Pfizer (NYSE:PFE | PFE Price Prediction) reports third-quarter results before the open on Tuesday, Nov. 3. Shares have gained 25% year to date. This report tests whether non-COVID growth and obesity progress…
Rich Duprey Parking six popular dividend stocks in a taxable account quietly hands the IRS a cut of every payout, and one holding in your portfolio is almost certainly the biggest culprit.
Three companies in pharmaceuticals, energy, and tobacco operate in entirely different worlds, and that separation is exactly the point for retirees who need their income to survive whatever the market throws at…
A closely tracked personalized melanoma vaccine met its main goal. Its effect on distant spread came in far smaller than an earlier study suggested in a late-stage trial. Moderna (NASDAQ:MRNA | MRNA…
A flashy dividend yield can mask serious cracks in a company's finances, and four well-known names are showing the same warning signs that preceded Whirlpool's sudden payout suspension earlier this year.
Full late-stage results for the personalized melanoma vaccine from Moderna (NASDAQ:MRNA | MRNA Price Prediction) and Merck (NYSE:MRK) came back positive, yet the selling hasn’t stopped. Those numbers landed short of the…
A late-stage melanoma vaccine report that was posted online and quickly pulled is driving a violent repricing in Moderna (NASDAQ:MRNA | MRNA Price Prediction) shares, even though its findings looked favorable on…
Pfizer's 5.7% dividend yield towers over Merck's, yet that gap may signal something retirees cannot afford to ignore. Before you chase the bigger payout, the coverage numbers behind each dividend tell a…
Moderna‘s (NASDAQ:MRNA | MRNA Price Prediction) push into cancer treatment is drawing heavy buying as a closely followed melanoma presentation approaches. Shares of Moderna are up 7% to $241.89 during the trading…
Soda, toothpaste, phone service, electricity, and prescription drugs all share one trait: people keep buying them when the economy turns ugly. Five companies built their businesses around that reality, and the way…
Eli Lilly just crushed earnings again and sits within striking distance of its all-time high, but a looming price war with Novo Nordisk and a dangerously concentrated revenue base raise real questions…
Pfizer's 5.8% yield looks tempting until you check what the dividend is actually costing the company relative to its cash generation. The math behind that payout is more uncomfortable than the headline…
A yield above 6% looks like a retirement lifeline until the math behind it starts to crack. Five familiar dividend names are flashing the kind of payout warnings that show up quietly…
Most retirees chase yield and end up with dividends that vanish the moment the economy wobbles. These five stocks solve that problem by pairing high payouts with the kind of coverage ratios…
Bristol Myers Squibb has raised its dividend for 17 straight years, but a looming patent cliff and $43 billion in debt put the pace of future increases on a collision course with…
